Key result
Diabetes shows no association with 1-year MACCE in elective PCI with bivalirudin.
Why the study?
It was unclear whether diabetes mellitus is an independent risk factor for thrombotic and bleeding events in patients anticoagulated with bivalirudin during elective PCI.
Does diabetes mellitus increase the risk of MACCE or bleeding events in patients undergoing elective PCI anticoagulated with bivalirudin?
Cohort (n=1,152)
Yes
Does diabetes mellitus increase the risk of MACCE or bleeding events in patients undergoing elective PCI anticoagulated with bivalirudin?
In patients undergoing elective PCI with bivalirudin anticoagulation, diabetes mellitus does not independently increase the risk of one-year thrombotic or bleeding events, whereas peripheral artery disease and low hemoglobin are significant predictors.
Answers are grounded in this paper and cite their sources.
DM was not associated with excess one-year MACCE or bleeding under bivalirudin in elective PCI; challenges general DM risk assumptions and leaves open prospective validation.
Background: Patients with diabetes mellitus (DM) are considered to increase the risk of thrombosis and bleeding. However, whether DM is an independent risk factor for events in patients anticoagulated with bivalirudin during elective percutaneous coronary intervention (PCI) is not clear. Methods: Patients anticoagulated with bivalirudin during elective PCI from January 2017 to August 2018 in 3 centers were enrolled. The primary endpoint of thrombotic events was major adverse cardiac and cerebrovascular events (MACCE, including all-cause death, myocardial infarction, ischemic revascularization, stent thrombosis, and stroke); the primary endpoint of bleeding events was Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding. Results: 1152 patients were finally enrolled. After one-year follow-up, 89 (7.7%) MACCE and 21 (1.8%) BARC 2, 3 or 5 bleeding occurred. Multivariate Cox regression analysis showed DM was not an independent risk factor for MACCE (hazard ratio [HR]: 1.029, 95% confidence interval [CI]: 0.674-1.573, P = .893), but peripheral artery disease (PAD) history (HR: 2.200, 95%CI: 1.290-3.751, P = .004) was an independent risk factor for MACCE. DM was not an independent risk factor for BARC 2, 3 or 5 bleeding (HR: 0.732, 95%CI: 0.293-1.831, P = .505), but PAD history (HR: 3.029, 95%CI: 1.102-8.332, P = .032) and low hemoglobin level (HR = 0.972, 95%CI: 0.947-0.998, P = .036) were independent risk factors for BARC 2, 3 or 5 bleeding. Conclusions: DM was not an independent risk factor for one-year thrombotic and bleeding events in patients anticoagulated with bivalirudin during elective PCI. More attention should be paid to PAD history and hemoglobin level to identify high-risk patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a cohort in Coronary heart disease requiring elective percutaneous coronary intervention (n=1,152). Diabetes Mellitus vs. Non-Diabetes Mellitus was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) (HR 1.029, 95% CI 0.674-1.573, p=0.893). Diabetes mellitus was not an independent risk factor for one-year major adverse cardiac and cerebrovascular events in patients anticoagulated with bivalirudin during elective PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: